Articles by Cailin Conner
Fixed-duration ibrutinib plus venetoclax provides durable PFS in patients with CLL.
Ibrutinib provides significantly longer PFS and OS benefits in CLL when compared to chlorambucil.
Oral targeted inhibitors are a viable treatment for patients with CLL with severe renal dysfunction.
Switching rates within 60 days were lower for patients treated with zanubrutinib compared with acalabrutinib and ibrutinib.
Quizartinib significantly improves long-term survival in FLT3-ITD+ AML by achieving deep and sustained reductions in MRD.
Combining HMAs with venetoclax significantly improves remission rates and survival but requires more healthcare resources.
SLC40A1 mRNA levels were significantly higher in AML patients compared with controls and were associated with poorer OS.
Achieving complete hematologic recovery before subsequent treatment cycles is associated with improved survival outcomes.
The investigators conceded the longer follow-up is needed but the results are promising.
The primary endpoints of the phase III ELEVATE-RR study were PFS, AEs, and events of clinical interest.
Reseserchers with the German CLL Study Group conducted a prospective analysis of karyotype complexity in patients with CLL.
Patients with mutated IGHV had a median PFS of 14.6 years compared with 4.2 years in patients with unmutated IGHV.
Japan's MHLW grants orphan drug designation to treatments designed for fewer than 50,000 patients.
Noteworthy regional disparities were noticed in treatment strategies.
Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021.
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
The combined average cost for the index hospitalization and two-year TE-related readmissions was $30,285.
The investigators sought to investigate the diagnostic landscape of polycythemia vera in LMICs.
Researchers developed the score because no early risk-stratification system has been validated in this setting.
The primary objective of the phase II portion was to evaluate the two-year PFS rate with the treatment.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.